ADAG

Adagene Inc.

Pharmaceutical Preparations · SIC 2834CIK 1818838Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$8.0M

Net Income FY2025

$(18.0M)

EPS (Basic, as reported)

$-0.30

Net Margin FY2025

-229.6%

ROE FY2025

-49.8%

Total Equity

$35.0M

Shares Out

59M

Business description

Adagene Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 20-F (foreign private issuer annual report) via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 2 → 8 +21.9% CAGR

Fiscal yearFY2018FY2019FY2020⚑FY2021FY2022FY2023FY2024FY2025

Revenue2011091808

Research & development(16)(16)(34)(68)(81)(37)(29)(22)

General & administrative(3)(3)(10)(14)(12)(9)(7)(7)

Operating income(17)(19)(43)(72)(84)(24)(36)(21)

Interest expense0000(1)(1)(1)0

Interest & investment income————0442

Pre-tax income(15)(16)(42)(71)(80)(17)(33)(18)

Income tax expense———(2)0(2)00

Net income(15)(16)(42)(73)(80)(19)(33)(18)

EPS — basic($0.94)($1.10)($2.67)($1.46)($1.48)($0.35)($0.59)($0.30)

EPS — diluted($0.94)($1.10)($2.67)($1.46)($1.48)($0.35)($0.59)($0.30)

Shares outstanding — basic (M)1515165054555659

Shares outstanding — diluted (M)1515165054555659

⚑ Weighted-average shares changed ×3.13 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.